Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuraPharmHKSE:01498 23 Days Payable is 236.10 as of Dec. 2025, which is 3% below its 10-year median of 243.11. GuruFocus rates HKSE:01498 with a GF Score™ of 23/100 and a GF Value™ of HK$0.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, PuraPharm ranks better than 89.38% on this metric.
PuraPharm's average Accounts Payable for the
six
months ended in Dec. 2025 was HK$101.9 Mil. PuraPharm's Cost of Goods Sold for the
six
months ended in Dec. 2025 was HK$78.8 Mil.
Hence, PuraPharm's Days Payable for the
six
months ended in Dec. 2025 was 236.10.
The historical rank and industry rank for PuraPharm's Days Payable or its related term are showing as below:
HKSE:01498'
s Days Payable Range Over the Past 10 Years
Min: 109.47 Med: 243.11 Max: 287.33
Current: 262.17
During the past 12 years, PuraPharm's highest Days Payable was 287.33. The lowest was 109.47. And the median was 243.11.
HKSE:01498's Days Payable is ranked better than 89.38% of 923
companies
in the Drug Manufacturers industry
Industry Median: 88.47
vs HKSE:01498: 262.17
PuraPharm's Days Payable
declined
from Dec. 2024 (302.55) to Dec. 2025 (236.10).
It may suggest that PuraPharmaccelerated paying its suppliers.
The historical data trend for PuraPharm's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Days Payable distribution charts can be found below:
* The bar in red indicates where PuraPharm's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PuraPharm's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm (HKSE:01498) has a Days Payable of 236.10 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PuraPharm and its competitors. This is near median its historical median of 243.11. Over the past decade, PuraPharm's Days Payable has ranged from 109.47 to 287.33. According to the industry distribution chart, PuraPharm ranks #98 out of 923 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is PuraPharm's Days Payable too high?
PuraPharm's current Days Payable of 236.10 is near median its 10-year median of 243.11. Over the past 10 years, this metric has ranged from a low of 109.47 to a high of 287.33. The Drug Manufacturers industry median Days Payable is 88.47. PuraPharm's value of 236.10 is 166.9% above this industry median. Based on the distribution chart, PuraPharm ranks #98 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PuraPharm ranks #98 out of 923 companies for Days Payable. This places PuraPharm in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.47. PuraPharm's value of 236.10 is 166.9% above this benchmark. Historically, PuraPharm's own Days Payable has ranged from 109.47 to 287.33 over the past decade. While the company's 10-year median is 243.11 vs. the industry median of 88.47, PuraPharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.47, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuraPharm's current Days Payable of 236.10 is 166.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PuraPharm and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuraPharm's current Days Payable is 236.10, which is near median its own 10-year median of 243.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current Days Payable is 236.10, which is near median its 10-year median of 243.11 and 166.9% above the Drug Manufacturers industry median of 88.47. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current Days Payable is 236.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuraPharm (HKSE:01498) Overvalued in 2026?
Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued.
The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51.
GuruFocus considers PuraPharm to be Possible Value Trap.
Key valuation signals for HKSE:01498:
Days Payable: 236.10 (near median its 10-year median of 243.11)
GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
Industry Position: 166.9% above the Drug Manufacturers median (#98 of 923)
No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score
Get the complete analysis for HKSE:01498
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01498 has been successfully added to your 
